Manal Mohamed Elhassan Taha, Siddig Ibrahim Abdelwahab, Sivakumar S Moni, Abdullah Farasani, Ieman A Aljahdali, Bassem Oraibi, Hassan Ahmad Alfaifi, Amal Hamdan Alzahrani, Ahmed Ali Jerah
{"title":"纳米增强免疫:疫苗佐剂研究中纳米粒子的文献计量分析。","authors":"Manal Mohamed Elhassan Taha, Siddig Ibrahim Abdelwahab, Sivakumar S Moni, Abdullah Farasani, Ieman A Aljahdali, Bassem Oraibi, Hassan Ahmad Alfaifi, Amal Hamdan Alzahrani, Ahmed Ali Jerah","doi":"10.1080/21645515.2024.2427464","DOIUrl":null,"url":null,"abstract":"<p><p>This study analyzed the growth, collaboration, citation trends, and emerging topics in nanoparticle-based vaccine and adjuvant research (NVAR) from 1977 to 2023, using data from the Scopus database. The field showed a steady growth rate of 7.53% per year. Leading researchers Jaafari, M.R. and Alving, C.R. contributed significantly to the field, with 24.22% of publications and 38.92% of total citations coming from the United States. International collaboration was very strong, particularly between the US, UK, Germany, China, and France. Key research topics include nanoparticles, immunotherapy, COVID-19, and vaccines with a focus on SARS-CoV-2 and malaria. Emerging topics include vaccine adjuvants, mRNA, and neutralizing antibodies. This study emphasizes the importance of ongoing collaboration and interdisciplinary efforts to advance the field of NVAR.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"20 1","pages":"2427464"},"PeriodicalIF":4.1000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11572201/pdf/","citationCount":"0","resultStr":"{\"title\":\"Nano-enhanced immunity: A bibliometric analysis of nanoparticles in vaccine adjuvant research.\",\"authors\":\"Manal Mohamed Elhassan Taha, Siddig Ibrahim Abdelwahab, Sivakumar S Moni, Abdullah Farasani, Ieman A Aljahdali, Bassem Oraibi, Hassan Ahmad Alfaifi, Amal Hamdan Alzahrani, Ahmed Ali Jerah\",\"doi\":\"10.1080/21645515.2024.2427464\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This study analyzed the growth, collaboration, citation trends, and emerging topics in nanoparticle-based vaccine and adjuvant research (NVAR) from 1977 to 2023, using data from the Scopus database. The field showed a steady growth rate of 7.53% per year. Leading researchers Jaafari, M.R. and Alving, C.R. contributed significantly to the field, with 24.22% of publications and 38.92% of total citations coming from the United States. International collaboration was very strong, particularly between the US, UK, Germany, China, and France. Key research topics include nanoparticles, immunotherapy, COVID-19, and vaccines with a focus on SARS-CoV-2 and malaria. Emerging topics include vaccine adjuvants, mRNA, and neutralizing antibodies. This study emphasizes the importance of ongoing collaboration and interdisciplinary efforts to advance the field of NVAR.</p>\",\"PeriodicalId\":49067,\"journal\":{\"name\":\"Human Vaccines & Immunotherapeutics\",\"volume\":\"20 1\",\"pages\":\"2427464\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2024-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11572201/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Vaccines & Immunotherapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/21645515.2024.2427464\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2024.2427464","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
Nano-enhanced immunity: A bibliometric analysis of nanoparticles in vaccine adjuvant research.
This study analyzed the growth, collaboration, citation trends, and emerging topics in nanoparticle-based vaccine and adjuvant research (NVAR) from 1977 to 2023, using data from the Scopus database. The field showed a steady growth rate of 7.53% per year. Leading researchers Jaafari, M.R. and Alving, C.R. contributed significantly to the field, with 24.22% of publications and 38.92% of total citations coming from the United States. International collaboration was very strong, particularly between the US, UK, Germany, China, and France. Key research topics include nanoparticles, immunotherapy, COVID-19, and vaccines with a focus on SARS-CoV-2 and malaria. Emerging topics include vaccine adjuvants, mRNA, and neutralizing antibodies. This study emphasizes the importance of ongoing collaboration and interdisciplinary efforts to advance the field of NVAR.
期刊介绍:
(formerly Human Vaccines; issn 1554-8619)
Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics.
Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.